Farah Fawaz Allogene Therapeutics

Farah Fawaz received her Ph.D. in cellular and Molecular Biology from the University of Michigan in Ann Arbor working on antibiotic production in Gram positive bacteria, and completed her post-doctoral work at the University of California San Francisco on bacterial pathogenesis and host cell signal transduction. Farah's first job was at Onyx Pharmaceuticals where she worked in the Research assay development group on oncolytic viruses. She then moved to the Development team at Berlex/Schering AG where she worked on assay development for gene therapy and allogeneic cell therapy products.

Following 6 years at Berlex, Farah joined Bayer, again in the development group where she headed the Analytical Development/Biochemistry team. She also had the opportunity to be the CMC lead for four programs while heading the Biochemistry laboratory, two of which made it to approval. After another 6 years in development, Farah moved to the product supply organization within Bayer where she headed the commercial QC Analytical Chemistry organization. From Bayer, she moved to Intarcia Therapeutics to build their commercial QC organization.

Farah then moved to Allogene as head of QC where she built the QC organization and supported the advancement of the various clinical programs. More recently, her role has been expanded to encompass external quality assurance activities and grow a team of Product Quality Leads (PQL) in addition to QC.